None
Quote | Command Security Corporation (NYSE:MOC)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $2.845 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Command Security Corporation (NYSE:MOC)
OATD-01 is a first-in-class chitotriosidase 1 (CHIT1) inhibitor with the potential to modify the course of disease in sarcoidosis and other interstitial lung diseases. Obtaining regulatory approvals in Denmark, France, Greece, Germany, and Norway enables the conduct of the Phase II clinic...
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's first administration of a chitotriosidase 1...
Message Board Posts | Command Security Corporation (NYSE:MOC)
Subject | By | Source | When |
---|---|---|---|
I hope this sale provides some additional contracts. | cj 13 | investorshub | 09/20/2018 1:04:35 AM |
* * $MOC Video Chart 08-02-18 * * | ClayTrader | investorshub | 08/02/2018 9:34:56 PM |
MOC share price looks like it's trying to | cj 13 | investorshub | 03/09/2018 3:12:29 PM |
29 percent year to year. Think the next | cj 13 | investorshub | 06/19/2017 5:50:21 PM |
I agree. I am definitely going to buy | Cboneofenglewood | investorshub | 06/18/2017 3:39:27 AM |
News, Short Squeeze, Breakout and More Instantly...
Command Security Corporation Company Name:
MOC Stock Symbol:
NYSE Market:
Command Security Corporation Website:
OATD-01 is a first-in-class chitotriosidase 1 (CHIT1) inhibitor with the potential to modify the course of disease in sarcoidosis and other interstitial lung diseases. Obtaining regulatory approvals in Denmark, France, Greece, Germany, and Norway enables the conduct of the Phase II clinic...
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's first administration of a chitotriosidase 1...
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will take a daily oral dose of 25 mg OATD-01 or...